Cargando…

The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial

AIM OF THE STUDY: The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety study with vemurafenib in patients with metastatic melanoma enrolled in Po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rutkowski, Piotr, Kozak, Katarzyna, Mackiewicz, Jacek, Krzemieniecki, Krzysztof, Nawrocki, Sergiusz, Wasilewska-Teśluk, Ewa, Kwinta, Łukasz, Wysocki, Piotr, Koseła-Paterczyk, Hanna, Świtaj, Tomasz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631301/ https://www.ncbi.nlm.nih.gov/pubmed/26557775 http://dx.doi.org/10.5114/wo.2015.54082

Ejemplares similares

The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
por: Sobczuk, Paweł, et al.
Publicado: (2022)

Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
por: Jagodzińska-Mucha, Paulina, et al.
Publicado: (2021)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors—A Sarcoma Reference Center Experience
por: Sobczuk, Paweł, et al.
Publicado: (2020)

Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF (V600) Mutation-Positive Melanoma
por: Czarnecka, Anna M., et al.
Publicado: (2021)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

The Long-Term Outcomes of Intensive Combined Therapy of Adult Patients with Localised Synovial Sarcoma
por: Kozak, Katarzyna, et al.
Publicado: (2020)

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage
por: Teterycz, Pawel, et al.
Publicado: (2019)

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
por: Placzke, Joanna, et al.
Publicado: (2023)

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
por: Kolenda, Tomasz, et al.
Publicado: (2019)

Serum markers in early-stage and locally advanced melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2019)

Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
por: Rogala, Paweł, et al.
Publicado: (2022)

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis
por: Wiater, Katarzyna, et al.
Publicado: (2013)

Efficacy and Safety of Hypofractionated Preoperative Radiotherapy for Primary Locally Advanced Soft Tissue Sarcomas of Limbs or Trunk Wall
por: Koseła-Paterczyk, Hanna, et al.
Publicado: (2021)

Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer—A Nation-Wide Study
por: Potocki, Paweł M., et al.
Publicado: (2023)

Treatment of Locally Advanced Merkel Cell Carcinoma—A Multi-Center Study
por: Dudzisz-Sledz, Monika, et al.
Publicado: (2022)

Management Strategies for Adults with Locally Advanced, Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa): Challenges and Solutions
por: Czarnecka, Anna M, et al.
Publicado: (2023)

Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma – real world multicenter cohort study
por: Słowińska, M., et al.
Publicado: (2022)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
por: Żołek, Teresa, et al.
Publicado: (2023)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

67P Detrimental effect of the COVID-19 pandemic on patients with adult extremity bone sarcoma: Reference center experience
por: Teterycz, P., et al.
Publicado: (2023)

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
por: Sondermann, Wiebke, et al.
Publicado: (2015)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
por: Chan, Sze Wai, et al.
Publicado: (2015)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2017)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
por: Dawidowska, Anna, et al.
Publicado: (2022)

Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications
por: Przybyl, Joanna, et al.
Publicado: (2014)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Predictive Biomarkers of Pathological Response to Neoadjuvant Chemoradiotherapy for Locally Advanced Soft Tissue Sarcomas
por: Szumera-Ciećkiewicz, Anna, et al.
Publicado: (2023)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
por: Shelledy, Lindsay, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ma1cvmjhont4jhb2psj9gjp0n5